Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA

Arndt Vogel • 9 Jul 2020
ESMO WCGIC 2020
Bile Duct Cancer Gastrointestinal Cancer Antibodies Cisplatin Gemcitabine Pembrolizumab
ABC-06 KEYNOTE-966

Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, discusses the rationale and study design of the KEYNOTE-966 trial (NCT04003636), evaluating pembrolizumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.

More from Arndt Vogel

2:17
The role of the PLATON Network in enhancing precision oncology
Arndt Vogel • 3 Jul 2023
3:14
RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC
Arndt Vogel • 3 Jul 2023
2:27
Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel • 3 Jul 2023
0:39
Analysis of the European/North American subgroup in the RATIONALE-301 trial
Arndt Vogel • 3 Jul 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals